深圳市新产业生物医学工程股份有限公司 深圳市新产业生物医学工程股份有限公司 投资者关系活动记录表 证券代码：300832 证券简称：新产业 编号：2025-004 投资者关系活动记录表 | 投资者关系 | □媒体采访 ☑业绩说明会 | | --- | --- | | 活动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | ☑其他 线上交流 | | 参与单位名 | 共计 120 家机构，163 名参会人员，详见附件《与会机构名单》； | | 称及人员姓 | 以及通过深交所"互动易"平台"云访谈"栏目参加新产业 2024 | | 名 | 年度业绩说明会的全体投资者 | | 时间 | 年 月 日-4 月 日 2025 4 27 30 | | | 23 | | | 栏目 | | 待人员姓名 | 副总经理兼财务总监 丁晨柳 | | | 独立董事 伍前辉 | | | 投资者关系负责人 吕宇宁 | | | 公司于 月 日发布了《2024 年年度报告》《2025 4 26 | | | 了线上和线下交流，本次交流涉及的经营要点及主要互动提问 | | 投资者关系 | | | 活动主要内 | 一、公司 年度及 ...

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于近日收到 日本特许厅颁发的1项《发明专利证书》，现将本次取得的发明专利具体情况公 告如下： 证券代码：300832 证券简称：新产业 公告编号：2025-038 深圳市新产业生物医学工程股份有限公司 关于公司获得发明专利证书的公告 专利权人：深圳市新产业生物医学工程股份有限公司 发明人：慕海林、徐方园、仇泽峰、程昱、黄任 专利申请日：2023年11月20日 深圳市新产业生物医学工程股份有限公司 发明名称：输送装置及核酸检测装置 日本专利号：第7663662号 授权公告日：2025年04月08日 上述专利保护技术为公司自主研发，本发明应用于全自动核酸检测分析系统 Molecision R8，涉及一种耗材输送装置，通过设置可横向移动的活动板以及可相 对于活动板沿竖向移动的第一承载台，使得本装置能够兼容不同高度的耗材，并 且能够实现耗材在载料位置和取料位置间的快速转移，大幅提高了耗材的转移效 率，进而提高了全自动核酸检测仪的检测速度。 本次取得的发明专利不会对公 ...

2025 年 4 月 30 日 公司研究 24 年营收稳步增长，创新成果不断涌现 研发投入持续加大，创新成果不断涌现：公司始终重视研发创新，2024 年研发 投入 4.54 亿元，同比增长 23.92%。持续的高投入为公司技术创新提供了坚实 保障。24 年公司在仪器和试剂研发方面成果丰硕，如更高通量的 MAGLUMIX10 化学发光免疫分析仪器发布；具有完全自主知识产权的开放式全自动样品处理系 统 SATLARST8 和智慧实验室平台 iXLAB 正式上市。众多新产品的推出和技术突 破，有助于公司进一步提升市场竞争力，巩固行业领先地位。 国内国际市场双轮驱动，市场份额逐步扩大：国内市场方面，公司通过持续推广 高速化学发光免疫分析仪及流水线产品，深化与国内大型医疗终端的合作，截至 2024 年末，国内三级医院客户达 1732 家，三级医院覆盖率为 44.93%。海外市 场上，公司通过区域化运营和本地化深耕，品牌国际影响力不断提升，公司已在 14 个核心国家建立运营体系，这些本地化的分支机构正成为区域业务增长的强 力引擎。 盈利预测、估值与评级：考虑到行业政策可能对公司带来的影响，我们下调公司 25-26 年的 ...

Core Insights - The company reported a revenue of 4.535 billion yuan for 2024, a year-on-year increase of 15.41%, driven by growth in overseas market sales [1] - The net profit attributable to shareholders was 1.828 billion yuan, up 10.57% year-on-year, while the non-recurring net profit was 1.720 billion yuan, an increase of 11.19% [1] - In Q4 2024, the company achieved a revenue of 1.121 billion yuan, a 9.75% increase year-on-year, but the net profit decreased by 4.73% to 445 million yuan [1] Revenue Breakdown - Domestic revenue reached 2.843 billion yuan, a 9.32% increase, primarily due to reagent price adjustments post-collection [2] - Overseas revenue was 1.684 billion yuan, a significant growth of 27.67%, with reagent income increasing by 26.47% [2] - The company established subsidiaries in Indonesia, Malaysia, and Thailand, and opened an office in Hanoi, Vietnam, with a successful launch of a subsidiary in South Korea in early 2025 [2] Product Performance - The flagship model MAGLUMI X8 saw stable growth, with annual sales of 1,048 units, bringing the total installed base to 3,701 units by the end of 2024 [2] - The SATLARS T8 fully automated laboratory automation line was successfully launched in June 2024, achieving 87 installations in its first year [3] Financial Metrics - The overall gross margin for 2024 was 72.07%, a slight decrease of 0.89 percentage points year-on-year [4] - The net profit margin decreased by 1.76 percentage points to 40.32% due to various cost factors [4] - In Q4 2024, the gross margin was 71.26%, with a notable decline influenced by accelerated installations of large equipment [4] Future Projections - Revenue forecasts for 2025-2027 are 5.155 billion, 6.010 billion, and 6.810 billion yuan, with year-on-year growth rates of 14%, 17%, and 13% respectively [5] - Projected net profits for the same period are 2.023 billion, 2.422 billion, and 2.794 billion yuan, reflecting growth rates of 11%, 20%, and 15% [5] - Earnings per share (EPS) are expected to be 2.57, 3.08, and 3.56 for 2025, 2026, and 2027 respectively [5]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Insights - The company's performance in 2024 met expectations, with a revenue of 4.535 billion yuan (up 15.41% year-on-year) and a net profit of 1.828 billion yuan (up 10.57% year-on-year). The growth is steady and aligns with forecasts [5] - In Q1 2025, the company achieved a revenue of 1.125 billion yuan (up 10.12% year-on-year) and a net profit of 438 million yuan (up 2.65% year-on-year). The domestic performance faced pressure due to inter-provincial alliance procurement policies, while overseas business continued to grow steadily [5] - The company has adjusted its profit forecasts for 2025-2026 and added a new forecast for 2027, expecting net profits of 2.049 billion yuan, 2.488 billion yuan, and 3.004 billion yuan for 2025, 2026, and 2027 respectively [5] - The company's overseas revenue reached 1.684 billion yuan in 2024 (up 27.67% year-on-year), accounting for 37% of total revenue, indicating strong growth in international markets [7] Financial Summary - In 2024, the company reported total revenue of 4.535 billion yuan, with a year-on-year growth of 15.4%. The net profit for the same year was 1.828 billion yuan, reflecting a growth of 10.6% [8] - The projected revenues for 2025, 2026, and 2027 are 5.126 billion yuan, 6.150 billion yuan, and 7.380 billion yuan respectively, with expected year-on-year growth rates of 13.0%, 20.0%, and 20.0% [8] - The company's gross margin is projected to be 71.0% in 2025, with a slight increase to 71.9% by 2027 [11]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is experiencing rapid growth in overseas business and optimizing its global installed structure [5] - Revenue forecasts for 2025-2027 are projected at 51.63 billion, 59.61 billion, and 69.28 billion RMB, with year-on-year growth rates of 13.84%, 15.45%, and 16.22% respectively [6] - Net profit attributable to the parent company for the same period is expected to be 20.12 billion, 23.43 billion, and 27.38 billion RMB, with growth rates of 10.06%, 16.41%, and 16.85% respectively [6] - The current price-to-earnings (P/E) ratios are 21x, 18x, and 15x for the years 2025, 2026, and 2027 [6] Financial Performance Summary - In 2024, the company achieved a revenue of 45.35 billion RMB (yoy +15.41%) and a net profit of 18.28 billion RMB (yoy +10.57%) [8] - For Q1 2025, the company reported a revenue of 11.25 billion RMB (yoy +10.12%) and a net profit of 4.38 billion RMB (yoy +2.65%) [8] - The company’s gross margin for 2024 was 72.26%, a slight decrease of 0.86 percentage points year-on-year, primarily due to an increase in the sales proportion of large and medium-sized instruments [8] - The company plans to continue increasing its investment in chemiluminescence and in vitro diagnostic products, with the launch of higher throughput instruments [8] Market Position and Strategy - The company has established operational systems in 14 core countries overseas, with significant sales growth in the Indian market, which exceeded 200 million RMB in 2024 [8] - The domestic revenue reached 28.43 billion RMB in 2024, with a year-on-year growth of 9.32%, driven by the promotion of high-speed instruments and production lines [8] - The company aims to enhance its market share in large medical institutions, achieving a coverage rate of 44.93% in tertiary hospitals by the end of 2024 [8]

Core Insights - The 2025 Cross-Strait Youth Employment and Entrepreneurship Development Exchange Conference and Industry Cooperation Promotion Conference are key events aimed at enhancing collaboration between Sichuan and Taiwan, focusing on new opportunities for integration and development [3][11] Industry Cooperation - Sichuan's economic scale has surpassed 6 trillion yuan, making it a prime destination for Taiwanese businesses looking to invest in mainland China's western region [4][10] - The region's diverse industrial base, including significant production in sectors like white liquor, solar energy, and electronics, provides a strong foundation for Taiwanese companies to explore [6][10] - Future cooperation is expected to focus on high-tech industries such as electronic information, artificial intelligence, and biopharmaceuticals, leveraging Taiwan's technological advantages and Sichuan's manufacturing capabilities [6][10] Youth Engagement - The conference highlighted the availability of 6,793 internship and employment opportunities for Taiwanese youth in Sichuan, showcasing the province's commitment to attracting young talent [7][8] - Various support measures have been implemented by Sichuan to facilitate Taiwanese youth's participation in cultural, educational, and entrepreneurial activities, enhancing the province's appeal [8][10] Strategic Vision - The collaboration between Taiwan and Sichuan is viewed as a "win-win" scenario, with both regions benefiting from their respective strengths in technology, manufacturing, and market access [10] - The theme of the conference, "Cultivating New Momentum for Development through Integration," emphasizes the importance of deepening ties and fostering mutual growth between the two regions [10][11]

Group 1 - Anhui provincial state-owned enterprises (SOEs) maintain strong performance, ranking in the top tier nationally with total assets of 4.8 trillion yuan, operating income of 249.3 billion yuan, and total profit of 21.7 billion yuan in Q1 2023 [1] - Significant progress in restructuring and integration in sectors such as culture and tourism, port and shipping, and coal, with key initiatives including the establishment of Anhui Cultural Tourism Investment Holding Group and strategic restructuring of coal-related entities [1] - Continuous double-digit growth in R&D investment for four consecutive years, with over 240 high-level innovation platforms established [1] Group 2 - By 2025, Anhui plans to enhance state capital investment in technological innovation, focusing on quantum information, fusion energy, and deep space exploration [2] - Development of a digital transformation action plan for provincial enterprises to promote high-end, intelligent, and green development in key industries [2] - Emphasis on emerging industries such as new materials, new energy, intelligent connected vehicles, high-end equipment, integrated circuits, and biomedicine [2]

Group 1 - The number of intellectual property disputes is increasing in emerging industries and technologies, with significant growth in cases related to high-end equipment manufacturing, new energy, biopharmaceuticals, biotechnology, and agricultural machinery [1] - In 2024, the Heilongjiang Provincial Court accepted 3,665 intellectual property first-instance cases and concluded 3,508 cases, achieving a resolution rate of 95.7% [1] - By the end of 2024, Heilongjiang Province will have 48,707 invention patents, representing a year-on-year growth of 5.55%, with a high-value invention patent ownership rate of 5.7 per 10,000 people, up 11.11% [3] Group 2 - The Heilongjiang Provincial Court has strengthened intellectual property protection in key areas and technologies, establishing a circuit trial point at Daqing Oilfield to resolve over 10 patent infringement disputes involving more than 10 million yuan [3] - The newly introduced Heilongjiang Provincial Intellectual Property Protection Regulations will take effect on April 26, 2025, featuring a series of institutional designs tailored to the province's strategic emerging industries and future industries [3][4] - The regulations encourage and support the transformation and application of scientific and technological achievements by establishing specialized institutions that integrate technology transformation and intellectual property operations [4]

Core Viewpoint - The company announced a cash dividend plan for the fiscal year 2024, proposing a distribution of 1.3 yuan per share, totaling approximately 1.021 billion yuan, which represents 55.86% of its net profit, marking the sixth cash distribution since its listing [1][2]. Financial Performance - The company reported a revenue of 4.535 billion yuan for the fiscal year, reflecting a year-on-year growth of 15.41% [2]. - The net profit reached 1.828 billion yuan, with a year-on-year increase of 10.57% [2]. - Basic earnings per share were reported at 2.3271 yuan, and the weighted average return on equity was 22.85% [2]. Dividend History - The company has a history of cash distributions since its listing, with the following details: - 2024: 10 shares for 13 yuan (total 1.021 billion yuan, dividend yield 1.85%) [2] - 2023: 10 shares for 10 yuan (total 786 million yuan, dividend yield 1.63%) [2] - 2022: 10 shares for 7 yuan (total 550 million yuan, dividend yield 1.51%) [2] - 2021: 10 shares for 6 yuan (total 472 million yuan, dividend yield 0.89%) [2] - 2020: 10 shares for 10 yuan (total 412 million yuan, dividend yield 0.62%) [2] - 2020 (interim): 10 shares for 15 yuan (total 619 million yuan, dividend yield 0.97%) [2] Market Activity - The stock experienced a net outflow of 12.258 million yuan from major funds today, with a total outflow of 34.114 million yuan over the past five days [2]. - The latest margin financing balance for the stock was reported at 854 million yuan, with a decrease of 8.9404 million yuan over the past five days, representing a decline of 1.04% [3]. Industry Comparison - Within the pharmaceutical and biotechnology sector, 248 companies have announced their 2024 dividend plans, with WuXi AppTec leading with a total cash distribution of 7.692 billion yuan [3]. - Other notable companies include Yunnan Baiyao and Aier Eye Hospital, with cash distributions of 2.114 billion yuan and 1.4887 billion yuan, respectively [3].